- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07854665
Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Tic Disorders/Tourette's Syndrome in Children and Adolescents
Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Tic Disorders/Tourette's Syndrome in Children and Adolescents: A Randomized Controlled Clinical Trial
The objective of this trial is to evaluate the effect of transcutaneous auricular vagus nerve stimulation compared to sham stimulation in improving chronic tic disorder or Tourette's syndrome in children and adolescents.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Participants will be randomly assigned to receive transcutaneous auricular vagus nerve stimulation or sham stimulation. Both interventions will be administered 5 times per week for 8 weeks. Study outcomes will be evaluated at baseline and at weeks 4, 8, and 12.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Simeng Wang, PHD
- Número de telefone: 8618811022134
- E-mail: 18811022134@163.com
Estude backup de contato
- Nome: Zhiyi Xiong, PHD
- Número de telefone: 8618811022104
- E-mail: zhiyixiong@foxmail.com
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- The first Affiliated Hospital of Zhejiang Chinese Medical University (FirstZhejiangCMU)
-
Contato:
- Simeng Wang, PHD
- Número de telefone: 8618811022134
- E-mail: 18811022134@163.com
-
Contato:
- Zhiyi Xiong, PHD
- Número de telefone: 8618811022104
- E-mail: zhiyixiong@foxmail.com
-
Investigador principal:
- Simeng Wang, PHD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Meets the DSM-5 diagnostic criteria for Tourette syndrome or chronic motor or vocal tic disorder;
- Age ≥6 and <18 years;
- YGTSS-TTS >15, or >10 for participants with motor tics or vocal tics only;
- If the participant is taking medication at enrollment, the medication regimen and dosage must have been stable for at least 4 weeks, with no planned changes in medication or dosage during the study;
- Has not received any non-pharmacological treatment for tics (e.g., acupuncture, transcranial magnetic stimulation, deep brain stimulation) within the preceding 8 weeks;
- Provides written informed consent.
Exclusion Criteria
- Mental or cognitive disability that would preclude participation in the study;
- Ear skin lesions, such as infection or eczema;
- An implanted cardiac pacemaker or other electronic medical device;
- Severe physical diseases, such as coronary heart disease, malignancy, or renal failure;
- Current participation in another clinical trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Transcutaneous auricular vagus nerve stimulation
Participants will receive transcutaneous auricular vagus nerve stimulation five times per week for eight consecutive weeks. |
Participants in the transcutaneous auricular vagus nerve stimulation group will receive stimulation at auricular acupoints located within the distribution area of the vagus nerve. A Hwato SDZ-II B electroacupuncture apparatus will be employed, with the two connecting clips of the same output lead attached to the acupoints on the same side. Disperse-dense wave stimulation will be applied, with the intensity adjusted according to the patient's tolerance, and each session will last 30 minutes. |
|
Comparador Falso: Sham stimulation
Participants will receive sham stimulation five times per week for eight consecutive weeks. |
Participants in the sham group will receive electrical stimulation at auricular acupoints located outside the distribution area of the vagus nerve, with a current intensity of 0.1 mA. All other procedures will be identical to those of the treatment group. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The Yale Global Tic Severity Scale Total Tic Score
Prazo: Week 8 (post treatment).
|
The Yale Global Tic Severity Scale (YGTSS) is a clinician-rated instrument designed to evaluate the severity of motor tics, phonic tics, and overall impairment over the preceding week. Motor and vocal tics are rated independently across five dimensions (number, frequency, intensity, complexity, and interference; range 0-5 each), and the dimension scores are summed to yield separate Motor and Vocal Tic scores (range 0-25 each) as well as a combined YGTSS Total Tic Score (range 0-50), with higher scores indicating greater tic severity. The YGTSS Impairment Rating captures tic-related distress and functional impact (range 0-50). The YGTSS Total Tic Score and the YGTSS Impairment Rating are summed to produce a YGTSS total score (range 0-100), with higher scores indicating greater overall severity. |
Week 8 (post treatment).
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The Yale Global Tic Severity Scale Total Score
Prazo: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
The Yale Global Tic Severity Scale (YGTSS) is a clinician-rated instrument assessing motor tics, vocal tics, and impairment over the preceding week. Motor and vocal tics are each rated on five dimensions (number, frequency, intensity, complexity, and interference; 0-5 each), yielding Motor and Vocal Tic scores (0-25 each) and a YGTSS Total Tic Score (0-50). The YGTSS Impairment (0-50) is added to the YGTSS Total Tic Score to produce a YGTSS Total Score (0-100), with higher scores indicating greater severity. |
Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
|
Children's Yale-Brown Obsessive Compulsive Scale
Prazo: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
The Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) will be used to assess the severity of obsessive-compulsive symptoms in children and adolescents. The total score of CY-BOCS ranges from 0 to 40, with higher scores indicate greater symptom severity. |
Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
|
Swanson, Nolan, and Pelham-IV-18
Prazo: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
The Swanson, Nolan, and Pelham Rating Scale version IV (SNAP-IV-18) will be used to assess symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. The total score of SNAP-IV-18 ranges from 0 to 54, with higher scores indicate more severe symptoms. |
Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
|
Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life
Prazo: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
The Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life (C&A-GTS-QOL) questionnaire will be used to assess health-related quality of life in children and adolescents with Tourette syndrome. The total score of C&A-GTS-QOL is typically transformed to a 0-100 scale, with higher scores indicating greater impairment and poorer quality of life. |
Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse Events
Prazo: Week 0 (baseline) to week 12.
|
An adverse event is any unexpected symptom, sign, or health condition occurring after initiation of study treatment, which may or may not be related to the study intervention. Pre-existing health conditions or diseases will only be considered as adverse events if they worsen after enrollment. |
Week 0 (baseline) to week 12.
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Doenças Genéticas, Congênitas
- Doenças Neurodegenerativas
- Distúrbios do Neurodesenvolvimento
- Distúrbios do Movimento
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Doenças dos Gânglios da Base
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Transtornos de Tique
- Síndrome de Tourette
Outros números de identificação do estudo
- FirstZhejiangCMU
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Deidentified participant data will be available from the study PI upon reasonable request after publication.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .